Robert Iannone - 16 Jan 2026 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Reporting relationship: EVP, Global Head of R&D & CMO
Issuer ticker: JAZZ
Reported as of: 16 Jan 2026
Net transaction value: -$708,602
SEC form: 4
Accepted by SEC: 21 Jan 2026, 19:53:17 UTC
Prior SEC filing: 19 Nov 2025
Next SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: By: /s/Paz Dizon, as attorney in fact For: Robert Iannone

Key filing fact

Robert Iannone filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 21 Jan 2026.

Key facts

This page summarizes Robert Iannone's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 21 Jan 2026, 19:53.

Change

Previous filing in this sequence was filed on 19 Nov 2025.
Current net transaction value: -$708,602.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001737329 Primary reporting owner

Iannone Robert

Relationship: EVP, Global Head of R&D & CMO
Address: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND
Signature: By: /s/Paz Dizon, as attorney in fact For: Robert Iannone
Signature date: 21 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JAZZ transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +11,699
Change %: +16%
Price: $0.000000
Shares after: 84,398
Date: 16 Jan 2026
Ownership: Direct
Footnotes: F1, F2

JAZZ transaction

Ordinary Shares

Tax liability

Transaction value: $708,602
Shares: -4,140
Change %: -4.9%
Price: $171.16
Shares after: 80,258
Date: 16 Jan 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.

Footnote F2

The Reporting Person acquired 71 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025.

Footnote F3

Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations.